CAPÍTULO 5: Manifestaciones extra musculoesqueléticas en espondiloartritis axial 2: enfermedad inflamatoria intestinal y otras

Rodolfo Peréz Alamino

Rodolfo Peréz Alamino Hospital Dr. Nicolás Avellaneda, Tucumán, Argentina

Palabras clave: espondiloartritis axial, enfermedad inflamatoria intestinal

Resumen

Las enfermedades inflamatorias intestinales (EII), incluyendo la enfermedad de Crohn (EC) y la colitis ulcerosa (CU), se presentan asociadas a la espondiloartritis axial radiográfica (EspAax-r) con una frecuencia reportada entre el 6-14%, significativamente mayor que en la población general. En la EspAax no radiográfica (EspAax-nr), la prevalencia parece ser similar. En un metaanálisis que evaluó la prevalencia de manifestaciones extra musculoesqueléticas en estas dos formas clínicas, se observó una diferencia de aproximadamente 1,4% a favor de la EspAax-r.

Biografía del autor/a

Rodolfo Peréz Alamino, Hospital Dr. Nicolás Avellaneda, Tucumán, Argentina

Hospital Dr. Nicolás Avellaneda

Citas

I. Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis 2015;74:65-73

II. Stolwijk C, Essers I, van Tubergen A, Boonen A, Bazelier M, De Bruin M, et al. The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study. Ann Rheum Dis 2015;74:1373-1378.

III. Essers I, Ramiro S, Stolwijk C, Blaauw M, Landewé R, van der Heijde D, et al. Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS. Rheumatology (Oxford) 2015;54:633-640.

IV. de Winter JJ, van Mens LJ, van der Heijde D, Landewé R, Baeten D. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta- analysis. Arthritis Res Ther 2016;18:196

V. Cypers H, Varkas G, Beeckman S, Debusschere K, Vogl T, Roth J, et al. Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. Ann Rheum Dis 2016; 75:1357-1362.

VI. Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 2006;20:451-471.

VII. Van Praet L, Van den Bosch FE, Jacques P, Carron P, Jans L, Colman R, et al. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis 2013;72:414-417.

VIII. Pérez-Alamino R, Maldonado-Ficco H, Maldonado-Cocco JA. Rheumatic manifestations in inflammatory bowel disease. A link between GI and rheumatology. Clin Rheumatol 2016;35:291-296.

IX. Gracey E, Vereecke L, McGovern D, Fröhling M, Schett G, Danese S, et al. Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis. Nature Rev Rheumatol 2020;16:415-433.

X. Arvikar SL, Fisher MC. Inflammatory bowel disease associated arthropathy. Curr Rev Musculoskelet Med 2011;4:123-131 .

XI. Sheth T, Pitchumoni CS, Das KM. Management of musculoskeletal manifestations in inflammatory bowel disease. Gastroenterol Res Pract 2015;2015:387891.

XII. Galloway M, Machado P. Axial spondyloarthritis. Medicine 2022;50-3.

XIII. Pouillon L, Bossuyt P, Vanderstukken J, Moulin D, Netter P, Danese S, et al. Management of patients with inflammatory bowel disease and spondyloarthritis. Expert Rev Clin Pharmacol 2017;10:1363-1374.

XIV. Fragoulis GE, Siebert S, McInnes IB. Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune- Mediated Diseases. Annu Rev Med 2016;67:337-353.

XV. Fries W. Inflammatory bowel disease-associated spondyloarthropathies. World J Gastroenterol 2009;15:2441-2442.

XVI. Liossis NS, Daoussis D. Is there a link between IL-23/IL-17 and developmental pathways such as the Wnt and Hedgehog pathway? Mediterr J Rheumatol 2017;28: 69-71.

XVII. Hasegawa E, Sonoda KH, Shichita T, Morita R, Sekiya T, Kimura A, et al. IL-23-independent induction of IL-17 from γδT cells and innate lymphoid cells promotes experimental intraocular neovascularization. J Immunol 2013;190:1778-1787.

XVIII. Siebert S, Millar NL, McInnes IB. Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials, or translation? Ann Rheum Dis 2019;(78)8:1015-1018.

XIX. Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis 2022;0:1-16.

XX. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf D G, Baerg R D, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-1094.

XXI. Hueber W, Sands B E, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PDR, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomized, double- blind placebo-controlled trial. Gut 2012;1693-1700.

XXII. Deodhar A, Gensler L, Sieper J, Clark M, Calderon C, Wanget Y, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis & Rheumatol 2019;71(2): 258-270.

XXIII. Baeten D, Østergaard M, Cheng-Chung Wei, Sieper J, Järvinen P, Tam L S, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, proof of concept, dose-finding phase 2 study. Ann Rheum Dis 2018;77:1295-1302.

XXIV. Siebert S, Millar N, McInnes I. Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation? Ann Rheum Dis 2019;78:1015-1018.

XXV. Cozzi G, Scagnellato L, Lorenzin M, Savarino E, Zingone F, Ometto F, et al. Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies. Nature Rev Rheumatol 2023;503-518.

XXVI. Park Hye-Sang, Laiz A, Sanchez-Vega J. Valve abnormalities, risk factors for heart valve disease and valve replacement surgery in spondyloarthritis. A systematic review of the literature. Front Cardiovasc Med 2021;8:719523.

XXVII. Kanathur N, Lee-Chiong T. Pulmonary manifestations of ankylosing spondylitis. Clin Chest Med 2010;(3):547-54.

XXVIII. Tang C, Moser F, Reveille J, Bruckel J, Weismanet M. Cauda equina syndrome in ankylosing spondylitis: challenges in diagnosis, management and pathogenesis. J Rheumatol 2019;(12):1582-1588.